StockNews.com Initiates Coverage on Atrion (NASDAQ:ATRI)

Equities research analysts at StockNews.com initiated coverage on shares of Atrion (NASDAQ:ATRI) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the medical instruments supplier’s stock.

Atrion Trading Up 0.4 %

Atrion stock opened at $451.98 on Friday. The firm has a market capitalization of $795.48 million, a P/E ratio of 42.48 and a beta of 0.66. The business has a 50-day moving average of $440.45 and a 200-day moving average of $398.47. Atrion has a 1 year low of $274.98 and a 1 year high of $602.59.

Atrion (NASDAQ:ATRI) last issued its earnings results on Friday, May 10th. The medical instruments supplier reported $1.59 EPS for the quarter. The firm had revenue of $47.33 million during the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%.

Hedge Funds Weigh In On Atrion

Several institutional investors have recently modified their holdings of the business. Copeland Capital Management LLC boosted its stake in Atrion by 56.4% in the 4th quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 31 shares during the period. Quadrant Capital Group LLC acquired a new position in shares of Atrion during the fourth quarter worth about $36,000. Harbor Investment Advisory LLC grew its holdings in shares of Atrion by 33.1% during the fourth quarter. Harbor Investment Advisory LLC now owns 189 shares of the medical instruments supplier’s stock worth $72,000 after buying an additional 47 shares in the last quarter. EntryPoint Capital LLC acquired a new stake in Atrion in the 1st quarter valued at approximately $91,000. Finally, Tower Research Capital LLC TRC lifted its stake in Atrion by 592.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 270 shares of the medical instruments supplier’s stock valued at $102,000 after acquiring an additional 231 shares in the last quarter. Institutional investors own 66.19% of the company’s stock.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.